Viral Inactivation Market (Updated Version Available)

Key Market Overview:

The viral inactivation market is expected to grow at a CAGR of 12.3% during the forecast period (2023-2030), with a projected market size of USD 1,208.22 million by 2030. The market was valued at USD 536.4 million in 2022. Factors driving market growth include the increasing demand for viral inactivation technologies in the biopharmaceutical industry, rising investments in R&D activities, and the growing prevalence of viral diseases. Additionally, the increasing adoption of single-use technologies and advancements in viral inactivation methods are expected to contribute to market growth.

Viral inactivation is a process that is used to eliminate or inactivate viruses in biological or pharmaceutical products such as vaccines, blood products, and gene therapy products. This process is important to ensure the safety and efficacy of these materials for use in medical, research, and industrial settings. Further, viral inactivation is achieved through various physical, chemical, and biological methods. One of the primarily used chemical methods is treatment with disinfectants or solvents such as chlorine, hydrogen peroxide, or quaternary ammonium compounds that are used to inactivate viruses. Such chemicals disrupt the viral envelope and denature the proteins and nucleic acids. Thus, the choice of method depends on the nature of the material and specific virus being targeted.

Moreover, the efficacy of viral inactivation methods is evaluated using statistical methods. Among such methods is the log reduction value (LRV) which indicates the degree to which the virus load has been reduced. For instance, a 3 LRV reduction means the viral load has been reduced by a factor of 1,000. Also, the type of sample that is intended for use needs to be highly purified and virtually free of infectious agents.

Further, growing incidences of autoimmune diseases are expected to propel the demand for viral inactivation. For instance, The American Autoimmune Related Diseases Association (AARDA), around 50 million Americans have at least one or multiple autoimmune diseases, where approximately 75 percent of the affected are women. Thus, rising demand for viral inactivation as immunostimulant adjuvants and antifungal drug delivery agents in vaccine formulations targeted for autoimmune and infectious diseases is projected to boost the market statistics during the forecast period.

Market Dynamics:

Driver:

Rising rate of autoimmune disorders and infectious diseases among population boosts the demand for viral inactivation in biopharmaceutical manufacturing for personalized approaches or treatment. Moreover, growing investments by biopharmaceutical companies in terms of safety and efficacy of drug interventions also boost the market demand. Also, increased expenditures on developments of the latest methods such as nanofiltration, and low pH treatment to offer higher levels of medicine safety as compared to conventional methods also propels the viral inactivation market growth.

Restraint:

High development and implementation costs of viral inactivation methods mainly hamper large-scale market adoption. Such expensive costs primarily affect the demand for viral inactivation especially in middle-income countries due to additional compliance requirements. Further, despite the usage of validated viral inactivation methods, the concerns related to incomplete inactivation of viruses also limits the wide adoption of such viral inactivation, especially in critical applications such as production of vaccine and blood products.

Opportunities:

The scope of advancements in existing viral inactivation methods is expected to offer lucrative opportunities for the market growth during the forecast period. Also, increased focus on investments in emerging technologies used to produce biologics and biosimilars is anticipated to create opportunities for market statistics in terms of effective production of pharmaceuticals in compliance with regulations and protocols.

Viral Inactivation Report Coverage:

Report Attributes	Report Details
Study Timeline	2017-2030
Market Size in 2030 (USD Billion)	1,208.22 Million
CAGR (2023-2030)	12.3 %
Base Year	2022
By Method	Solvent/Detergent Inactivation, Pasteurization (Heating), Acidic pH Inactivation
By Product	Kits, Reagents, Systems, Services
By Application	Blood & Blood Products, Stem Cell Products, Tissue & Tissue Products, Vaccines, and Therapeutics, Cellular & Gene Therapy Products
By End Use	Contract Research Organizations, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Others
By Geography	Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia] Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey] North America [United States, Canada, Mexico] Middle East & Africa [GCC, North Africa, South Africa] South America [Brazil, Argentina, Columbia, Chile, Peru]
Key Players	Thermo Fisher Scientific Inc., Sigma-Aldrich (Merck KGaA), VWR International, LLC, Pall Corporation (Danaher Corporation), Rad Source Technologies, Sartorius AG, Texcell, WuXi Biologics, Macopharma

Request Sample

Viral Inactivation Market Segmentation:



By Method

The method segment is divided into solvent/detergent inactivation, pasteurization (heating), and acidic pH inactivation. The solvent/detergent inactivation segment accounted for highest share contribution to the viral inactivation market statistics in 2022. In latest circumstances, solvent/ detergent method finds major usage used in production of recombinant proteins and human-plasma–derived proteins. Such complete dependence on solvent or detergent to solubilize a lipid membrane structure of viral envelope results in the prevention of a virus from infecting or binding to cells, thus rendering the virus inactive. Thus, the aforementioned factor attributes to segmental growth, boosting the overall market growth. Moreover, pasteurization (heating) segment is also anticipated to support the market growth during the forecast period in terms of volume and value. Pasteurization has been at the forefront of the biopharmaceutical industry in terms of a viral risk mitigation strategy for prevention of costly contamination events. Hence, such a heavy reliance on pasteurization for maintaining product quality is estimated to support segmental growth.

By Product

The product segment is categorized into kits, reagents, systems, and services. The kits segment is estimated to contribute significant shares to the market growth during the forecast period. Such kits play a crucial role in carrying out tests on serum, urine, plasma, saliva, and other samples with ease, even in home care settings, further expected to boost the segmental growth. Also, systems segment is projected to register the fastest CAGR during the forecast period. The systems for viral inactivation are fully automated that provide the ability to complete low pH virus inactivation in terms of continuous incoming elution stream with reduced involvement of operator. Also, favorable usage of such viral inactivation systems for operations in continuous mode or batch for flexible facility fit is projected to support segmental growth.

By Application

The application segment is categorized into blood & blood products, stem cell products, tissue & tissue products, vaccines and therapeutics, cellular & gene therapy products. The vaccines and therapeutics segment contributed highest shares to the market growth in 2022. The large adoption of inactivated vaccines and therapeutics for elimination of specific disease-causing germs supports the demand for such live attenuated vaccines. Further, the blood & blood products segment is estimated to contribute significant shares to the market growth during the forecast period. Favorable demand for pathogen inactivation of blood products such as platelets, plasma, red blood cells, and plasma derivatives to reduce infectious risks to a recipient is expected to support the segmental growth in terms of safety and medical effectiveness.

By End User

The end-use segment comprises the contract research organizations, pharmaceutical and biotechnology companies, academic research institutes, and others. The contract research organizations (CROs) segment contributed the highest share contribution to the market growth in 2022. Rising expenditures on production of new biological therapeutic products by such CROs support the demand for viral inactivation to inactivate lipid-coat enveloped viruses within such therapeutics. Moreover, pharmaceutical and biotechnology companies segment is expected to support the viral inactivation market growth in terms of volume. High dependence on viruses as vectors for the creation of pharmaceuticals requires virus inactivation for removing their pathogenic parts without hampering the gene-delivery capacities, which is anticipated to propel the demand for viral inactivation by pharmaceutical and biotechnology organizations.

By Region

The regional segment includes Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. North America dominates the market of viral inactivation in terms of highest market share over 41.6% in 2022. This is due to the large-scale prevalence of advanced medical technologies along with rising expertise in research and development of advanced viral inactivation methods with a focus on efficiency.



However, Asia Pacific is anticipated to exhibit the fastest CAGR during the forecast period. The factors attributed to such market growth in Asia Pacific region are increased prevalence of chronic diseases and growing government as well as private ventures expenditures on the development of healthcare infrastructure.

Viral Inactivation Market Competitive Landscape:

The market of viral inactivation is highly competitive market due to the large presence of established market players. Such companies offer a wide range of products and services to meet growing demand for vaccines and other biological products. Also, the rising focus on product and patient safety is estimated to push such market players toward introducing safe and reliable biopharmaceutical products. Following are companies that comprise latest market environment–

• Thermo Fisher Scientific Inc.
• Sigma-Aldrich (Merck KGaA)
• VWR International, LLC
• Pall Corporation (Danaher Corporation)
• Rad Source Technologies
• Sartorius AG
• Texcell
• WuXi Biologics
• Macopharma

Recent Developments:

• In February 2022, HPG Co., Ltd. has launched a new product named Epigallocatechin Gallate which is a water soluble solution and has excellent storage stability. The launch is estimated to help company introduce several innovations of viral inactivation in varying environmental conditions.

• In March 2022, Thermo Fisher Scientific introduced a latest viral transport medium that allows the rapid inactivation and transfer of the SARS-CoV-2 virus. Such inactivation is attained by balancing the usage of viral RNA in in-vitro diagnostic testing methods.

• In November 2022, Merck invests approximately 290 Million Euros in its biosafety testing capacity located at Rockville, Maryland, USA. Such investment in a testing facility is expected to significantly increase the ability of the company to conduct biosafety testing along with offering analytical development services.